MX2015017136A - Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma. - Google Patents
Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.Info
- Publication number
- MX2015017136A MX2015017136A MX2015017136A MX2015017136A MX2015017136A MX 2015017136 A MX2015017136 A MX 2015017136A MX 2015017136 A MX2015017136 A MX 2015017136A MX 2015017136 A MX2015017136 A MX 2015017136A MX 2015017136 A MX2015017136 A MX 2015017136A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- complications
- diabetes
- association
- magnesium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición específica para una administración oral de magnesio, para su uso en el tratamiento de diabetes tipo 2 o complicaciones, de la misma, en asociación con una composición destinada al tratamiento de la diabetes tipo 2 o las complicaciones de la misma .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13305789.3A EP2813217A1 (fr) | 2013-06-11 | 2013-06-11 | Composition pour administration orale de magnésium, en association avec une composition destinée à traiter le diabète de type 2 ou ses complications |
PCT/EP2014/061518 WO2014198591A1 (fr) | 2013-06-11 | 2014-06-03 | Composition pour administration orale de magnésium, en association avec une composition destinée a traiter le diabète de type 2 ou ses complications |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015017136A true MX2015017136A (es) | 2016-07-08 |
Family
ID=48651951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015017136A MX2015017136A (es) | 2013-06-11 | 2014-06-03 | Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma. |
Country Status (8)
Country | Link |
---|---|
US (1) | US10653718B2 (es) |
EP (2) | EP2813217A1 (es) |
JP (2) | JP2016521735A (es) |
CA (1) | CA2915326C (es) |
ES (1) | ES2769551T3 (es) |
MX (1) | MX2015017136A (es) |
PT (1) | PT3007683T (es) |
WO (1) | WO2014198591A1 (es) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA73467B (en) | 1972-02-25 | 1973-10-31 | Hoffmann La Roche | Mineral salts containing preparation |
FR2677546B1 (fr) | 1991-06-12 | 1994-01-21 | Fabienne Joanny | Composition therapeutique pour liberation prolonge de magnesium. |
AU2583397A (en) | 1996-04-10 | 1997-10-29 | Chronorx, Llc | Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions |
US6376549B1 (en) * | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
WO2001022943A1 (en) | 1999-09-29 | 2001-04-05 | H J Davis Fine Chemicals Cc | A slow release pharmaceutical composition comprising a magnesium oxychloride cement |
US6887492B2 (en) | 2000-12-14 | 2005-05-03 | Leiner Health Services Corp. | Magnesium plus interactive agent delivery |
FR2855412B1 (fr) | 2003-05-27 | 2007-05-25 | Menvielle Bourg Fabienn Joanny | Composition a liberation prolongee de magnesium, et son application dans le domaine therapeutique, cosmetique et nutritionnel |
FR2931359B1 (fr) | 2008-05-20 | 2012-12-21 | Menvielle Bourg Fabienne Joanny | Utilisation d'une matrice pour administration orale de magnesium a liberation prolongee, et composition contenant cette matrice |
-
2013
- 2013-06-11 EP EP13305789.3A patent/EP2813217A1/fr not_active Withdrawn
-
2014
- 2014-06-03 WO PCT/EP2014/061518 patent/WO2014198591A1/fr active Application Filing
- 2014-06-03 CA CA2915326A patent/CA2915326C/fr active Active
- 2014-06-03 PT PT147275705T patent/PT3007683T/pt unknown
- 2014-06-03 ES ES14727570T patent/ES2769551T3/es active Active
- 2014-06-03 US US14/897,737 patent/US10653718B2/en active Active
- 2014-06-03 EP EP14727570.5A patent/EP3007683B1/fr active Active
- 2014-06-03 JP JP2016518918A patent/JP2016521735A/ja active Pending
- 2014-06-03 MX MX2015017136A patent/MX2015017136A/es active IP Right Grant
-
2019
- 2019-04-04 JP JP2019072090A patent/JP2019131589A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016521735A (ja) | 2016-07-25 |
CA2915326A1 (fr) | 2014-12-18 |
CA2915326C (fr) | 2021-11-23 |
EP3007683B1 (fr) | 2019-10-30 |
EP3007683A1 (fr) | 2016-04-20 |
EP2813217A1 (fr) | 2014-12-17 |
JP2019131589A (ja) | 2019-08-08 |
WO2014198591A1 (fr) | 2014-12-18 |
PT3007683T (pt) | 2020-02-04 |
US20160120900A1 (en) | 2016-05-05 |
US10653718B2 (en) | 2020-05-19 |
ES2769551T3 (es) | 2020-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017502297A1 (en) | Antibacterial compounds | |
MX2021010033A (es) | Composiciones microencapsuladas de cannabinoides. | |
MX2019009132A (es) | Composiciones bacterianas sinergicas y sus metodos de produccion y usos. | |
MY172578A (en) | Oral dosing of glp-1 compounds | |
IN2014CN02616A (es) | ||
MX2015010125A (es) | Derivados de piridazinona-amidas. | |
MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
EA201791110A1 (ru) | Сублингвальное введение рилузола | |
MX2015015518A (es) | Metodos y composiciones para el tratamiento del cancer. | |
MX2014002159A (es) | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. | |
PH12017500315A1 (en) | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection | |
EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
PH12017501290A1 (en) | Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide | |
MX2015008310A (es) | Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -. | |
IN2014DN07326A (es) | ||
NZ707636A (en) | Ingenol-derived compounds that can be used for treating cancer | |
MX2016012758A (es) | Composicion hiperosmolar de acido hialuronico. | |
MX2016006544A (es) | Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas. | |
MX2016007955A (es) | Pirrol carboxamidas iii fluorometil-sustituidas. | |
AR098670A1 (es) | Inhibidor de sglt1 | |
MX2016007951A (es) | Pirrol carboxamidas iv fluorometil-sustituidas. | |
MX2015017136A (es) | Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |